Validation Study of Rapid Assays of Bioburden, Endotoxins and Other Contamination

• Published in: Biocontrol Science Vol. 21; no. 2; pp. 63 - 72
• Main Author: SHINTANI, HIDEHARU
• Format: Journal Article
• Language: English
• Published: Japan The Society for Antibacterial and Antifungal Agents, Japan 2016; Japan Science and Technology Agency
• Subjects: Bioburden; Contamination; Drug Contamination - legislation & jurisprudence; Endotoxin; Endotoxins - adverse effects; Endotoxins - analysis; Environmental Monitoring - methods; Environmental Monitoring - standards; Food Contamination - analysis; Food Contamination - legislation & jurisprudence; Humans; Microbiological Techniques - methods; Microbiological Techniques - standards; Rapid Assay; Reproducibility of Results; Technology, Pharmaceutical - methods; Technology, Pharmaceutical - standards
• ISSN: 1342-4815; 1884-0205
• DOI: 10.4265/bio.21.63

Microbial testing performed in support of pharmaceutical and biopharmaceutical productionfalls into three main categories: detection (qualitative), enumeration (quantitative), and characterization/identification. Traditional microbiological methods are listed in the compendia and discussed by using the conventional growth-based techniques, which are labor intensive and time consuming. In general, such tests require several days of incubation for microbial contamination (bioburden) to be detected, and therefore management seldom is able to take proactive corrective measures. In addition, microbial growth is limited by the growth medium used and incubation conditions, thus impacting testing sensitivity, accuracy, and reproducibility. 　For more than 20 years various technology platforms for rapid microbiological methods (RMM) have been developed, and many have been readily adopted by the food industry and clinical microbiology laboratories. Their use would certainly offer drug companies faster test turnaround times to accommodate the aggressive deadlines for manufacturing processes and product release. Some rapid methods also offer the possibility for real-time microbial analyses, enabling management to respond to microbial contamination events in a more timely fashion, and can provide cost savings and higher efficiencies in quality control testing laboratories. Despite the many proven business and quality benefits and the fact that the FDA's initiative to promote the use of process analytical technology (PAT) includes rapid microbial methods, pharmaceutical and biopharmaceutical industries have been somewhat slow to embrace alternative microbial methodologies for several reasons. The major reason is that the bioburden counts detected by the incubation method and rapid assay are greatly divergent. 　The use of rapid methods is a dynamic field in applied microbiology and one that has gained increased attention nationally and internationally over time. This topic has been extensively addressed at conferences and in published documents around the world. More recently, the use of alternative methods for control of the microbiological quality of pharmaceutical products and materials used in pharmaceutical production has been addressed by the compendia in an attempt to facilitate implementation of these technologies by pharmaceutical companies. The author presents some of the rapid method technologies under evaluation or in use by pharmaceutical microbiologists and the current status of the implementation of alternative microbial methods.